P16 gene hypermethylation and hepatocellular carcinoma: A systematic review and meta-analysis

World Journal of Gastroenterology

Volumn 17, Issue 25, 2011, Pages 3043-3048

  Zang, Jia Jie ^a   Xie, Feng ^a   Xu, Jin Fang ^a   Qin, Ying Yi ^a   Shen, Rong Xi ^a   Yang, Jia Mei ^a   He, Jia ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Liver cirrhosis; Meta analysis; Odds ratio; P16 hypermethylation

Indexed keywords

PROTEIN P16;

CANCER RISK; CASE CONTROL STUDY; DNA METHYLATION; GENE INACTIVATION; HUMAN; INCIDENCE; INFORMATION PROCESSING; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; META ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; SYSTEMATIC REVIEW;

EID: 79960257770     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i25.3043     Document Type: Review

References (33)

1. Bosch FX, Ribes J, Borràs J. Epidemiology of primary liver cancer. Semin Liver Dis 1999; 19: 271-285
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917
3. Sheu JC. Molecular mechanism of hepatocarcinogenesis. J Gastroenterol Hepatol 1997; 12: S309-S313
4. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368: 753-756
5. Okamoto A, Demetrick DJ, Spillare EA, Hagiwara K, Hussain SP, Bennett WP, Forrester K, Gerwin B, Serrano M, Beach DH. Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci U S A 1994; 91: 11045-11049
6. Sherr CJ. Cancer cell cycles. Science 1996; 274: 1672-1677
7. Biden K, Young J, Buttenshaw R, Searle J, Cooksley G, Xu DB, Leggett B. Frequency of mutation and deletion of the tumor suppressor gene CDKN2A (MTS1/p16) in hepatocellular carcinoma from an Australian population. Hepatology 1997; 25: 593-597
8. Moher D, Liberati A, Tetzlaff J, Altman DG. Reprint-- preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. Phys Ther 2009; 89: 873-880
9. Bero L, Rennie D. The Cochrane Collaboration. Preparing, maintaining, and disseminating systematic reviews of the effects of health care. JAMA 1995; 274: 1935-1938
10. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.0.2 (updated September 2009). The Cochrane Collaboration, 2009. Accessed March 1, 2010
11. Woodward M. Epidemiology: design and data analysis. 2nd ed. Boca Raton: Chapman and Hall/CRC Press, 2005
12. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101
13. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634
14. Formeister EJ, Tsuchiya M, Fujii H, Shpyleva S, Pogribny IP, Rusyn I. Comparative analysis of promoter methylation and gene expression endpoints between tumorous and nontumorous tissues from HCV-positive patients with hepatocellular carcinoma. Mutat Res 2010; 692: 26-33
15. Zhu YZ, Zhu R, Fan J, Pan Q, Li H, Chen Q, Zhu HG. Hepatitis B virus X protein induces hypermethylation of p16(INK4A) promoter via DNA methyltransferases in the early stage of HBV-associated hepatocarcinogenesis. J Viral Hepat 2010; 17: 98-107
16. Zhang C, Guo X, Jiang G, Zhang L, Yang Y, Shen F, Wu M, Wei L. CpG island methylator phenotype association with upregulated telomerase activity in hepatocellular carcinoma. Int J Cancer 2008; 123: 998-1004
17. Liu WJ, Wang L, Wang JP, Li JQ, Zhang CQ, Zheng L, Yuan YF. [Correlations of CpG island methylator phenotype and OPCML gene methylation to carcinogenesis of hepatocellular carcinoma]. Ai Zheng 2006; 25: 696-700
18. Qin Y, Liu JY, Li B, Sun ZL, Sun ZF. Association of low p16INK4a and p15INK4b mRNAs expression with their CpGislands methylation with human hepatocellular carcinogenesis. World J Gastroenterol 2004; 10: 1276-1280
19. Lee S, Lee HJ, Kim JH, Lee HS, Jang JJ, Kang GH. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol 2003; 163: 1371-1378
20. Schagdarsurengin U, Wilkens L, Steinemann D, Flemming P, Kreipe HH, Pfeifer GP, Schlegelberger B, Dammann R. Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma. Oncogene 2003; 22: 1866-1871
21. Zhang YJ, Ahsan H, Chen Y, Lunn RM, Wang LY, Chen SY, Lee PH, Chen CJ, Santella RM. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma. Mol Carcinog 2002; 35: 85-92
22. Yu J, Zhang HY, Ma ZZ, Lu W, Wang YF, Zhu JD. Methylation profiling of twenty four genes and the concordant methylation behaviours of nineteen genes that may contribute to hepatocellular carcinogenesis. Cell Res 2003; 13: 319-333
23. Kondo Y, Kanai Y, Sakamoto M, Mizokami M, Ueda R, Hirohashi S. Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis--A comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular carcinoma. Hepatology 2000; 32: 970-979
24. Saito Y, Kanai Y, Sakamoto M, Saito H, Ishii H, Hirohashi S. Expression of mRNA for DNA methyltransferases and methyl-CpG-binding proteins and DNA methylation status on CpG islands and pericentromeric satellite regions during human hepatocarcinogenesis. Hepatology 2001; 33: 561-568
25. Wong IH, Lo YM, Yeo W, Lau WY, Johnson PJ. Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients. Clin Cancer Res 2000; 6: 3516-3521
26. Liew CT, Li HM, Lo KW, Leow CK, Chan JY, Hin LY, Lau WY, Lai PB, Lim BK, Huang J, Leung WT, Wu S, Lee JC. High frequency of p16INK4A gene alterations in hepatocellular carcinoma. Oncogene 1999; 18: 789-795
27. Zhang YL, Xiao WH, Zhang YM, Liang HJ. Detection and significance of p16 and its methylation in primary hepatocellular carcinoma. Disan Junyi Daxue Xuebao 2002; 24: 1182-1184
28. Xu J, Li X, Gao RT, Xu XC, Zhai ZM, Ma JL, Ye SL. Detection of methylation of p16 and p15 gene promoter in hepatocellular carcinoma. Anhui Yike Daxue Xuebao 2006; 41: 365-368
29. Kaneto H, Sasaki S, Yamamoto H, Itoh F, Toyota M, Suzuki H, Ozeki I, Iwata N, Ohmura T, Satoh T, Karino Y, Satoh T, Toyota J, Satoh M, Endo T, Omata M, Imai K. Detection of hypermethylation of the p16(INK4A) gene promoter in chronic hepatitis and cirrhosis associated with hepatitis B or C virus. Gut 2001; 48: 372-377
30. Roncalli M, Bianchi P, Bruni B, Laghi L, Destro A, Di Gioia S, Gennari L, Tommasini M, Malesci A, Coggi G. Methylation framework of cell cycle gene inhibitors in cirrhosis and associated hepatocellular carcinoma. Hepatology 2002; 36: 427-432
31. Fang JY, Xiao SD. Alteration of DNA methylation in gastrointestinal carcinogenesis. J Gastroenterol Hepatol 2001; 16: 960-968
32. Chu HJ, Heo J, Seo SB, Kim GH, Kang DH, Song GA, Cho M, Yang US. Detection of aberrant p16INK4A methylation in sera of patients with liver cirrhosis and hepatocellular carcinoma. J Korean Med Sci 2004; 19: 83-86
33. Matsuda Y. Molecular mechanism underlying the functional loss of cyclindependent kinase inhibitors p16 and p27 in hepatocellular carcinoma. World J Gastroenterol 2008; 14: 1734-1740